January 20, 2017

Practices interested in becoming Office Based Opioid Treatment (OBOT) providers under the ARTS benefit to obtain the higher reimbursement for opioid counseling and the new payment for substance abuse coordination available to providers selected as OBOTs need to do the following: 

Register clinicians including physicians, NPs, PAs, behavioral health professionals, and administrators for the VDH Addiction Disease Management trainings at:  http://www.dmas.virginia.gov/Content_pgs/bh-sud.aspx.  This is a great opportunity for physicians, NPs, and PAs to obtain their buprenorphine waiver and for physicians, NPs, PAs, nurses, pharmacists, behavioral health professionals, and administrators to learn about the Office-Based Opioid Treatment (OBOT) clinical and financial model.  Physicians who already have their buprenorphine waiver can still attend the 4 hours on the OBOT clinical and financial model.  DMAS strongly encourages teams of prescribers (physicians and NPs/PAs) and behavioral health professionals to attend the trainings. 

Verify that your team of a licensed buprenorphine-waivered practitioner and a licensed behavioral health professional, practicing in a variety of practice settings including primary care clinics, outpatient health system clinics, psychiatry clinics, Federally-Qualified Health Centers, Community Service Boards, Local Health Departments, and physician’s offices, who meets the requirement on the ARTS OBOT Credentialing Checklist (click here to download)OBOTs do not require a separate license from the Department of Behavioral Health and Developmental Services.  All clinicians must be licensed by the appropriate Board at the Department of Health Professions. 

Complete the OBOT Attestation and Application (click here to download) and the ARTS OBOT Organizational Staff Roster (click here to download) and submit to DMAS via fax: 804-452-5450 and simultaneously to Magellan and all the Medicaid health plans in your region.

Please note that submission of an OBOT Attestation and Application does not guarantee that providers meet the OBOT requirements.  Providers will need to be recognized by DMAS and credentialed by the health plans and Magellan as an OBOT to bill for the higher reimbursement for opioid counseling and new payment for substance use care coordination.  OBOT providers can only bill these codes for Medicaid members with moderate to severe opioid use disorder who are receiving Medication Assisted Treatment (buprenorphine containing product or injectable naltrexone) and counseling from the OBOT.  DMAS will be providing a series of webinars on Medicaid billing and OBOT billing for interested providers.

Opioid Treatment Programs that dispense buprenorphine products will need to be credentialed as an OBOT to receive the benefits of no service authorization for buprenorphine as well as the OBOT payment model.